Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Paxirasol aerosol applied in daily 3 x 5 puff doses in the treatment of silicosis patients is found to be a well tolerated drug form. In the course of the 21-day therapy especially coughing and chest pain were moderated, but the product also controlled, the catarrhal coat formation on the mucosa. It influenced abundant expectoration and dispnoea beneficially. During the therapy the laboratory parameters did not change. The objective respiratory parameters improved but the change was non-significant. Paxirasol aerosol is found useful in the treatment of chronic bronchitis accompanying silicosis. Evaluable side-effects were not registered.
 ...
PMID:Clinical observations with Paxirasol aerosol in patients suffering from chronic bronchitis accompanying silicosis. 134 26

This study involved 25 elderly (> 65 years old) patients (pts) with unresectable non small cell lung cancer (NSCLC) who were not eligible for polychemotherapy. The diagnosis of NSCLC was histologically or cytologically documented, and all of them had measurable or evaluable disease. The median age of the patients was 71 (range 65-77); 9 had been pretreated. The pts received 25 mg/m2 of vinorelbine weekly or bi-weekly depending on the results of blood tests. The treatment continued until disease progression or tolerance. No complete response was achieved: 3 pts (12%) had a partial response (RP) (8-12-14 months), 13 (52%) stable disease (SD) with an improvement in symptoms, such as cough and/or pain, and 9 pts (36%) progressed. Compliance with the therapy was acceptable. The main toxicity was hematological: neutropenia was observed in 16 pts, with only 1 case of grade 4 neutropenia without sepsis; grade 1-2 anemia occurred in 8 patients. The other toxicities included grade 1-2 neurotoxicity in 8 pts, chemical phlebitis in 2 pts and grade 3 cardiotoxicity reversible with medical treatment in 1 patient. The median survival time was 10 months (lower quartile 5 months, upper quartile 23 months) (Kaplan and Meyer method). Vinorelbine can be considered a rational choice in elderly pts with advanced NSCLC who are not suitable for aggressive polychemotherapy, with the aim of improving their quality of life in terms of symptoms and outpatient treatment.
 ...
PMID:Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients. 926 13